Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.46 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854233 | 0.87 | ALDH1A1 (0.37) | SMYD3ALDH1A1TP53MAPTMAPK1 | |
| SCHEMBL4199097 | 0.86 | SMYD3 (0.45) | SMYD3EPHX2 | |
| SCHEMBL4202518 | 0.86 | SMYD3 (0.44) | SMYD3AHRCMA1EPHX2 | |
| SCHEMBL4195347 | 0.85 | SMYD3 (0.43) | SMYD3AHRCMA1EPHX2 | |
| SCHEMBL622063 | 0.79 | SMYD3 (0.56) | SMYD3AHRCMA1ALDH1A1MAPK1 | |
| SCHEMBL31210109 | 0.79 | SMYD3 (0.56) | SMYD3AHRCMA1ALDH1A1MAPK1 | |
| SCHEMBL13854246 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TP53MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL5792436 | 0.78 | SMYD3 (0.52) | SMYD3AHRCMA1 | |
| SCHEMBL8232914 | 0.78 | SMYD3 (0.52) | SMYD3AHRCMA1 | |
| SCHEMBL4218125 | 0.78 | SMYD3 (0.52) | SMYD3AHRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| CN-101410107-A | MIF inhibitors | CORTICAL PTY LTD (AU) | 2009-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | SMYD3 4031/4885AHR 2958/4885CMA1 92/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | SMYD3 3217/4885AHR 2285/4885CMA1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.